NCT04315233 | University of Utah|Novartis|Acrotech Biopharma | Metastatic Breast Cancer|Recurrent Ovarian Carcinoma | May 3, 2021 | Phase 1 |
NCT03078751 | Novartis Pharmaceuticals|Novartis | Breast Cancer | June 20, 2017 | Phase 2 |
NCT03834740 | St. Joseph´s Hospital and Medical Center, Phoenix|Ivy Brain Tumor Center|Barrow Neurological Institute | Glioblastoma Multiforme|Glioma of Brain | December 21, 2018 | Early Phase 1 |
NCT01777776 | Array BioPharma | Locally Advanced Metastatic BRAF Mutant Melanoma | July 2013 | Phase 1|Phase 2 |
NCT05569187 | Novartis Pharmaceuticals|Novartis | Breast Cancer | March 23, 2021 | |
NCT03839823 | Novartis Pharmaceuticals|Novartis | Breast Cancer | February 25, 2019 | Phase 2 |
NCT03294694 | Dana-Farber Cancer Institute|Novartis | Metastatic Hormone-Receptor-Positive (HR&addition;) Breast Cancer|HER2-Negative Breast Cancer|Metastatic Epithelial Ovarian Cancer | November 8, 2017 | Phase 1 |
NCT05766410 | National Taiwan University Hospital | Breast Cancer|Hormone Receptor-positive Breast Cancer|Hormone Therapy | September 16, 2022 | Phase 2 |
NCT05816655 | Korea University Guro Hospital | Metastatic Breast Cancer | May 31, 2023 | Phase 2 |
NCT05843253 | Nationwide Children´s Hospital|Novartis | High Grade Glioma|Diffuse Intrinsic Pontine Glioma|Anaplastic Astrocytoma|Glioblastoma|Glioblastoma Multiforme|Diffuse Midline Glioma, H3 K27M-Mutant|Metastatic Brain Tumor|WHO Grade III Glioma|WHO Grade IV Glioma | August 15, 2023 | Phase 2 |
NCT03008408 | M.D. Anderson Cancer Center | Recurrent Endometrial Carcinoma|Recurrent Endometrial Endometrioid Adenocarcinoma|Refractory Endometrial Carcinoma|Refractory Endometrial Endometrioid Adenocarcinoma|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8 | August 18, 2017 | Phase 2 |
NCT03439046 | Novartis Pharmaceuticals|Novartis | Breast Cancer | February 2, 2018 | Phase 3 |
NCT03477396 | City of Hope Medical Center|National Cancer Institute (NCI) | Estrogen Receptor and+or Progesterone Receptor Positive|HER2+Neu Negative|Stage IV Breast Cancer AJCC v6 and v7 | June 14, 2018 | Phase 2 |
NCT05467891 | Oana Danciu|Novartis Pharmaceuticals|Hoosier Cancer Research Network | Locoregional Recurrence|Hormone Receptor-positive Breast Cancer|HER2-negative Breast Cancer | September 13, 2022 | Phase 2 |
NCT05759949 | Relay Therapeutics, Inc. | PIK3CA Mutation|Solid Tumor, Adult|HER2-negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Unresectable Solid Tumor|Hormone Receptor Positive Tumor | March 29, 2023 | Phase 1 |
NCT02571829 | Hadassah Medical Organization | Liposarcoma|Soft Tissue Sarcoma | May 2016 | Phase 2 |
NCT02933736 | Nader Sanai|Novartis|Ivy Brain Tumor Center|Barrow Neurological Institute|St. Joseph´s Hospital and Medical Center, Phoenix | Glioblastoma Multiforme|Meningioma | October 2016 | Early Phase 1 |
NCT03555877 | German Breast Group | Breast Cancer Metastatic | March 15, 2018 | Phase 2 |
NCT03096912 | Assaf-Harofeh Medical Center | Liposarcomas, Dedifferentiated|Liposarcoma - Well Differentiated|Liposarcoma; Mixed Type|Soft-Tissue Sarcoma | July 2016 | Phase 2 |
NCT02813135 | Gustave Roussy, Cancer Campus, Grand Paris|National Cancer Institute, France | Pediatric Cancer | August 3, 2016 | Phase 1|Phase 2 |
NCT03434262 | St. Jude Children´s Research Hospital|Novartis Pharmaceuticals | Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Ganglioglioma|Anaplastic Meningioma|Anaplastic Oligodendroglioma|Pleomorphic Xanthoastrocytoma, Anaplastic|Atypical Teratoid+Rhabdoid Tumor|Brain Cancer|Brain Tumor|Central Nervous System Neoplasms|Choroid Plexus Carcinoma|CNS Embryonal Tumor With Rhabdoid Features|Ganglioneuroblastoma of Central Nervous System|CNS Tumor|Embryonal Tumor of CNS|Ependymoma|Glioblastoma|Glioma|Glioma, Malignant|Medulloblastoma|Medulloblastoma; Unspecified Site|Medulloepithelioma|Neuroepithelial Tumor|Neoplasms|Neoplasms, Neuroepithelial|Papillary Tumor of the Pineal Region (High-grade Only)|Pediatric Brain Tumor|Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)|Pineoblastoma|Primitive Neuroectodermal Tumor|Recurrent Medulloblastoma|Refractory Brain Tumor|Neuroblastoma. CNS|Glioblastoma, IDH-mutant|Glioblastoma, IDH-wildtype|Medulloblastoma, Group 3|Medulloblastoma, Group 4|Glioma, High Grade|Neuroepithelial Tumor, High Grade|Medulloblastoma, SHH-activated and TP53 Mutant|Medulloblastoma, SHH-activated and TP53 Wildtype|Medulloblastoma, Chromosome 9q Loss|Medulloblastoma, Non-WNT Non-SHH, NOS|Medulloblastoma, Non-WNT+Non-SHH|Medulloblastoma, PTCH1 Mutation|Medulloblastoma, WNT-activated|Ependymoma, Recurrent|Glioma, Recurrent High Grade|Glioma, Recurrent Malignant|Embryonal Tumor, NOS|Glioma, Diffuse Midline, H3K27M-mutant|Embryonal Tumor With Multilayered Rosettes (ETMR)|Ependymoma, NOS, WHO Grade III|Ependymoma, NOS, WHO Grade II|Medulloblastoma, G3+G4|Ependymoma, RELA Fusion Positive | March 5, 2018 | Phase 1 |
NCT02300987 | Novartis Pharmaceuticals|Novartis | Teratoma | February 26, 2015 | Phase 2 |
NCT04000529 | Novartis Pharmaceuticals|Novartis | Non-small Cell Lung Carcinoma|Head and Neck Squamous Cell Carcinoma|Esophageal SCC|Gastrointestinal Stromal Tumors|Colorectal Cancer | July 30, 2019 | Phase 1 |
NCT02934568 | Novartis Pharmaceuticals|Novartis | Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | December 15, 2016 | Phase 2 |
NCT03822468 | Novartis Pharmaceuticals|Novartis | Breast Cancer | June 11, 2019 | Phase 2 |
NCT05870579 | Novartis Pharmaceuticals|Novartis | Breast Cancer | September 30, 2023 | Phase 1 |
NCT04801966 | Peter MacCallum Cancer Centre, Australia | Cancer | September 23, 2021 | Not Applicable |
NCT02712723 | Qamar Khan|Novartis Pharmaceuticals|University of Kansas Medical Center | Breast Cancer | February 2016 | Phase 2 |
NCT05691400 | University of Michigan Rogel Cancer Center | CYP3A4*22 | August 2023 | Phase 4 |
NCT03740334 | Dana-Farber Cancer Institute|Novartis | Acute Lymphoblastic Leukemia ALL | January 30, 2019 | Phase 1 |
NCT05296746 | SOLTI Breast Cancer Research Group|Novartis|UNICANCER | Breast Cancer Stage II | May 3, 2022 | Phase 2 |
NCT02333370 | Novartis Pharmaceuticals|Novartis | Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer | February 4, 2015 | Phase 1 |
NCT04852081 | Blokhin´s Russian Cancer Research Center | Breast Cancer Stage IV | January 1, 2021 | |
NCT03179956 | Fox Chase Cancer Center | Squamous Cell Carcinoma of the Head and Neck | April 2, 2018 | Early Phase 1 |
NCT05563220 | Stemline Therapeutics, Inc. | Breast Cancer|Metastatic Breast Cancer | January 24, 2023 | Phase 1|Phase 2 |
NCT05452213 | Institut fuer Frauengesundheit|AGO Breast Study Group e.V.|Novartis Pharmaceuticals | Breast Cancer|Breast Neoplasms|Breast Neoplasm Female|Breast Cancer Female|HER2-negative Breast Cancer|Hormone Receptor-positive Breast Cancer|Advanced Breast Cancer | October 12, 2022 | Phase 4 |
NCT05358249 | Novartis Pharmaceuticals|Novartis | KRAS G12C Mutant Solid Tumors|Carcinoma, Non-Small Cell Lung|Carcinoma, Non-Small-Cell Lung|Non-Small Cell Lung Cancer|Non-Small Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Colorectal Cancer|Colorectal Carcinoma|Colorectal Neoplasms|Colorectal Tumors|Neoplasms, Colorectal | October 24, 2022 | Phase 1|Phase 2 |
NCT03081234 | Novartis Pharmaceuticals|Novartis | Breast Cancer | March 31, 2018 | Phase 3 |
NCT02703571 | Novartis Pharmaceuticals|Novartis | Solid Tumors for Phase Ib|Pancreatic Cancer for Phase II|Colorectal Cancer for Phase II | June 29, 2016 | Phase 1 |
NCT04657679 | Georgetown University|Medstar Health Research Institute|Breast Cancer Research Foundation|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) | Breast Cancer | May 20, 2021 | Phase 4 |
NCT02370706 | Novartis Pharmaceuticals|Novartis | Myelofibrosis | May 21, 2015 | Phase 1 |
NCT02732119 | Novartis Pharmaceuticals|Novartis | Breast Cancer | June 14, 2016 | Phase 1|Phase 2 |
NCT05664893 | Centre Antoine Lacassagne | HER2 Negative Breast Cancer Not Immediately Operated | June 26, 2023 | Phase 1|Phase 2 |
NCT03616587 | AstraZeneca | ER&addition; HER2- Advanced Breast Cancer | October 11, 2018 | Phase 1 |
NCT03387020 | Pediatric Brain Tumor Consortium|National Cancer Institute (NCI) | CNS Embryonal Tumor, Not Otherwise Specified|Malignant Glioma|Recurrent Atypical Teratoid+Rhabdoid Tumor|Recurrent Childhood Ependymoma|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Medulloblastoma|Refractory Diffuse Intrinsic Pontine Glioma | January 13, 2018 | Phase 1 |
NCT05252416 | Blueprint Medicines Corporation | Advanced Solid Tumors|HR&addition; Breast Cancer|CCNE1 Amplification|HER2-negative Breast Cancer|Ovarian Cancer|Endometrial Cancer|Gastric Cancer|Esophageal Adenocarcinoma|Carcinosarcoma | April 7, 2022 | Phase 1|Phase 2 |
NCT01898845 | Novartis Pharmaceuticals|Novartis | Advanced Solid Tumors | May 2013 | Phase 1 |
NCT03114527 | Fox Chase Cancer Center | Soft Tissue Sarcoma | August 8, 2017 | Phase 2 |
NCT05827081 | Novartis Pharmaceuticals|Novartis | Early Breast Cancer | September 29, 2023 | Phase 3 |
NCT03070301 | Memorial Sloan Kettering Cancer Center|Novartis|Dana-Farber Cancer Institute|M.D. Anderson Cancer Center | Neuroendocrine Tumors | February 27, 2017 | Phase 2 |
NCT03671330 | Novartis Pharmaceuticals|Novartis | Breast Cancer | August 29, 2018 | Phase 2 |
NCT03905343 | Swiss Group for Clinical Cancer Research|The Belgian Society of Medical Oncology | Breast Cancer | June 25, 2019 | Phase 3 |
NCT02599363 | Abramson Cancer Center at Penn Medicine | Advanced Breast Cancer | January 2016 | Phase 1 |
NCT05319873 | Jonsson Comprehensive Cancer Center|Seagen Inc.|Novartis | Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Locally Advanced HER2-Positive Breast Carcinoma|Metastatic HER2-Positive Breast Carcinoma|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8 | April 7, 2022 | Phase 1|Phase 2 |
NCT04213404 | National Taiwan University Hospital|Novartis | Head and Neck Squamous Cell Carcinoma | March 13, 2020 | Phase 1 |
NCT02985125 | Georgetown University|Novartis|University of Texas Southwestern Medical Center|Cedars-Sinai Medical Center|Virginia Mason Hospital+Medical Center | Metastatic Pancreatic Adenocarcinoma | May 4, 2017 | Phase 1|Phase 2 |
NCT03283384 | Borstkanker Onderzoek Groep|Novartis|Philips Healthcare | Breast Neoplasms | June 15, 2019 | Phase 2 |
NCT03355794 | Children´s Hospital Medical Center, Cincinnati|Novartis | Diffuse Intrinsic Pontine Glioma|Malignant Glioma of Brain|High Grade Glioma|Bithalamic High Grade Glioma|Brainstem Glioma|Glioblastoma|Anaplastic Astrocytoma | November 14, 2017 | Phase 1 |
NCT05207709 | SOLTI Breast Cancer Research Group|Novartis|Alliance Foundation Trials, LLC. | Metastatic Breast Cancer | March 28, 2022 | Phase 3 |
NCT02344472 | Prof. W. Janni|Roche Pharma AG|Novartis Pharmaceuticals|Eisai GmbH|Celgene Corporation|University of Ulm | Metastatic Breast Cancer | September 2015 | Phase 3 |
NCT02431481 | Novartis Pharmaceuticals|Novartis | Normal Renal Function|Impaired Renal Function | October 23, 2015 | Phase 1 |
NCT02154776 | Novartis Pharmaceuticals|Novartis | Advanced or Metastatic Breast Cancer | June 27, 2014 | Phase 1 |
NCT03944434 | Fondazione Sandro Pitigliani|Novartis | Breast Cancer | December 27, 2018 | Phase 2 |
NCT02422615 | Novartis Pharmaceuticals|Novartis | Advanced Breast Cancer | June 9, 2015 | Phase 3 |
NCT02429089 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Squamous Cell Carcinoma of the Head and Neck | April 2015 | Phase 1 |
NCT02345824 | University of Virginia|Novartis Pharmaceuticals | Glioblastoma|Glioma | March 2016 | Phase 1 |
NCT05153135 | Novartis Pharmaceuticals|Novartis | Metastatic Breast Cancer | May 8, 2020 | |
NCT04256941 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8 | May 31, 2019 | Phase 2 |
NCT02088684 | Novartis Pharmaceuticals|Novartis | Breast Cancer | May 19, 2014 | Phase 1 |
NCT02925234 | The Netherlands Cancer Institute|Amgen|AstraZeneca|Bayer|Bristol-Myers Squibb|Novartis|Roche Pharma AG|Merck Sharp & Dohme LLC|Boehringer Ingelheim|Ipsen|Eisai Inc.|Pfizer|Clovis Oncology, Inc.|Eli Lilly and Company|Janssen, LP | Cancer|Tumors|Neoplasm|Neoplasia | August 2016 | Phase 2 |
NCT04943497 | Novartis Pharmaceuticals|Novartis | Breast Cancer | July 27, 2021 | |
NCT05429502 | Novartis Pharmaceuticals|Innovative Therapies For Children with Cancer Consortium|Novartis | Neuroblastoma | December 27, 2022 | Phase 1|Phase 2 |
NCT05051956 | Namik Kemal University | Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors | October 1, 2021 | |
NCT02754011 | UNICANCER|Novartis | Breast Cancer | February 2, 2017 | Phase 1 |
NCT02974725 | Novartis Pharmaceuticals|Novartis | Non-Small Cell Lung Cancer|Melanoma | February 24, 2017 | Phase 1 |
NCT05384119 | Tvardi Therapeutics, Incorporated | Breast Cancer | January 9, 2023 | Phase 1|Phase 2 |
NCT03009201 | OHSU Knight Cancer Institute|Novartis Pharmaceuticals|Oregon Health and Science University | Advanced Soft Tissue Sarcoma|Locally Advanced Angiosarcoma|Locally Advanced Leiomyosarcoma|Locally Advanced Liposarcoma|Locally Advanced Malignant Peripheral Nerve Sheath Tumor|Locally Advanced Myxofibrosarcoma|Locally Advanced Undifferentiated Pleomorphic Sarcoma|Metastatic Angiosarcoma|Metastatic Epithelioid Sarcoma|Metastatic Fibrosarcoma|Metastatic Liposarcoma|Metastatic Malignant Peripheral Nerve Sheath Tumor|Metastatic Myxofibrosarcoma|Metastatic Soft Tissue Sarcoma|Metastatic Synovial Sarcoma|Metastatic Undifferentiated Pleomorphic Sarcoma|Myxofibrosarcoma|Pleomorphic Rhabdomyosarcoma|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Undifferentiated (Embryonal) Sarcoma|Unresectable Leiomyosarcoma|Unresectable Liposarcoma|Unresectable Malignant Peripheral Nerve Sheath Tumor|Unresectable Soft Tissue Sarcoma|Unresectable Synovial Sarcoma|Unresectable Undifferentiated Pleomorphic Sarcoma | March 10, 2017 | Phase 1 |
NCT05625087 | UNICANCER|Novartis|Breast Cancer Research Foundation | Breast Cancer Stage IV | June 2023 | Phase 2 |
NCT02586675 | H. Lee Moffitt Cancer Center and Research Institute|Novartis | Breast Cancer|Breast Cancer - Female|Breast Cancer - Male | February 23, 2016 | Phase 1 |
NCT04055493 | West German Study Group|Novartis|Genomic Health�, Inc. | Breast Cancer Female | July 2, 2019 | Phase 3 |
NCT01543698 | Pfizer | Solid Tumors Harboring a BRAF V600 Mutation | May 28, 2012 | Phase 1|Phase 2 |
NCT04964934 | AstraZeneca | ER-Positive HER2-Negative Breast Cancer | June 30, 2021 | Phase 3 |
NCT02555189 | Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University | Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Prostate Carcinoma Metastatic in the Bone|Stage IV Prostate Cancer | December 1, 2015 | Phase 1|Phase 2 |
NCT05900206 | Karolinska University Hospital | Breast Cancer | June 1, 2023 | Phase 2 |
NCT02187783 | Novartis Pharmaceuticals|Novartis | Tumors With CDK4+6 Pathway Activation | August 25, 2014 | Phase 2 |
NCT02278120 | Novartis Pharmaceuticals|Novartis | Advanced Metastatic Breast Cancer | November 20, 2014 | Phase 3 |
NCT02292550 | Novartis Pharmaceuticals|Novartis | Non-small Cell Lung Cancer | May 14, 2015 | Phase 1 |
NCT04417621 | Novartis Pharmaceuticals|Novartis | Melanoma | October 30, 2020 | Phase 2 |
NCT05038631 | Novartis Pharmaceuticals|Novartis | Breast Cancer | | |
NCT05573555 | Pfizer|Arvinas Estrogen Receptor, Inc. | Breast Cancer | March 1, 2023 | Phase 2 |
NCT04862663 | AstraZeneca | Locally Advanced (Inoperable) or Metastatic Breast Cancer | May 10, 2021 | Phase 3 |
NCT04585724 | Emory University|National Cancer Institute (NCI) | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8|Metastatic Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Prognostic Stage IV Breast Cancer AJCC v8 | June 12, 2020 | Phase 1 |
NCT01857193 | Novartis Pharmaceuticals|Novartis | Breast Cancer | September 6, 2013 | Phase 1 |
NCT02734615 | Novartis Pharmaceuticals|Novartis | Advanced or Metastatic ER&addition; Breast Cancer | June 14, 2016 | Phase 1 |
NCT02607124 | Children´s Hospital Medical Center, Cincinnati|Novartis | High Grade Glioma|Diffuse Intrinsic Pontine Glioma|Bithalamic High Grade Glioma | April 2016 | Phase 1|Phase 2 |
NCT04802759 | Hoffmann-La Roche | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | June 20, 2021 | Phase 1|Phase 2 |
NCT03248427 | SOLTI Breast Cancer Research Group|Novartis | Breast Cancer | July 13, 2017 | Phase 2 |
NCT03484923 | Novartis Pharmaceuticals|Novartis | Melanoma | September 10, 2018 | Phase 2 |
NCT03237390 | Mayo Clinic|National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm|Metastatic Malignant Solid Neoplasm | January 4, 2018 | Phase 1 |
NCT03090165 | Kari Wisinski|Novartis|Big Ten Cancer Research Consortium|University of Wisconsin, Madison | Triple Negative Breast Cancer | May 7, 2018 | Phase 1|Phase 2 |
NCT05508906 | Olema Pharmaceuticals, Inc.|Novartis | Metastatic Breast Cancer|Advanced Breast Cancer|HR-positive Breast Cancer|HER2-negative Breast Cancer | August 31, 2022 | Phase 1 |
NCT02608216 | University of Pennsylvania | Breast Neoplasm|Metastatic Breast Cancer|Rb&addition; Breast Cancer | November 2015 | Phase 1 |
NCT03056833 | Ronald Buckanovich|University of Pittsburgh | Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Carcinoma | June 10, 2017 | Phase 1 |
NCT01958021 | Novartis Pharmaceuticals|Novartis | Advanced, Metastatic Breast Cancer | December 17, 2013 | Phase 3 |
NCT03673124 | Gynecologic Oncology Group|Novartis|GOG Foundation | Low Grade Serous Carcinoma | December 14, 2018 | Phase 2 |
NCT02420691 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Novartis | Advanced Digestive System Neuroendocrine Neoplasm|Duodenal Neuroendocrine Tumor G1|Functional Pancreatic Neuroendocrine Tumor|Gastric Neuroendocrine Tumor|Intermediate Grade Lung Neuroendocrine Neoplasm|Low Grade Lung Neuroendocrine Neoplasm|Nonfunctional Pancreatic Neuroendocrine Tumor|Thymus Neoplasm | August 25, 2015 | Phase 2 |
NCT05203172 | Pfizer | Solid Tumors | July 5, 2022 | Phase 4 |
NCT01872260 | Novartis Pharmaceuticals|Novartis | Breast Cancer | October 22, 2013 | Phase 1|Phase 2 |
NCT02941926 | Novartis Pharmaceuticals|Novartis | Breast Cancer | November 30, 2016 | Phase 3 |
NCT02414724 | Roswell Park Cancer Institute|Novartis | Lymphoma|Solid Neoplasm | May 2015 | Phase 1 |
NCT03701334 | Novartis Pharmaceuticals|Translational Research in Oncology|Novartis | Early Breast Cancer | December 7, 2018 | Phase 3 |
NCT02388620 | Novartis Pharmaceuticals|Novartis | Normal Hepatic Function|Impaired Hepatic Function | March 25, 2015 | Phase 1 |
NCT02657928 | Mayo Clinic|National Cancer Institute (NCI) | Estrogen Receptor Positive|Postmenopausal|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma | July 8, 2016 | Phase 2 |
NCT02494921 | Rahul Aggarwal|Novartis|University of California, San Francisco | Prostate Cancer | November 20, 2015 | Phase 1|Phase 2 |
NCT04116541 | Centre Leon Berard | Malignant Solid Tumor | January 28, 2020 | Phase 2 |
NCT03096847 | Novartis Pharmaceuticals|Novartis | Advanced Metastatic Breast Cancer | October 24, 2016 | Phase 3 |
NCT02035813 | Prof. W. Janni|University of Ulm | HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer|HER2-negative Circulating Tumor Cells|Postmenopausal Female Patients | January 2014 | Phase 2 |
NCT02524119 | University of Texas Southwestern Medical Center|Novartis Pharmaceuticals | Hepatocellular Carcinoma | April 2016 | Phase 2 |
NCT01237236 | Novartis Pharmaceuticals|Novartis | Advanced Solid Tumor|Lymphomas | December 21, 2010 | Phase 1 |
NCT01919229 | Novartis Pharmaceuticals|Novartis | Early Breast Cancer | October 2013 | Phase 2 |
NCT05697146 | Novartis Pharmaceuticals|Novartis | Breast Cancer | December 13, 2022 | |
NCT03333343 | Novartis Pharmaceuticals|Novartis | EGFR-mutant Non-small Cell Lung Cancer | January 29, 2018 | Phase 1 |
NCT05996107 | University of Michigan Rogel Cancer Center | Breast Cancer | October 2023 | Phase 1 |
NCT01781572 | Pfizer | Locally Advanced or Metastatic NRAS Mutant Melanoma | June 2013 | Phase 1|Phase 2 |
NCT03956654 | Universitaire Ziekenhuizen KU Leuven | Breast Cancer | December 11, 2018 | |
NCT01747876 | Novartis Pharmaceuticals|Novartis | Malignant Rhabdoid Tumors (MRT)|Neuroblastoma | May 28, 2013 | Phase 1 |
NCT02343172 | Novartis Pharmaceuticals|Novartis | Liposarcoma | March 13, 2015 | Phase 1 |
NCT03424005 | Hoffmann-La Roche|Seagen Inc.|Gilead Sciences | Breast Cancer | April 2, 2018 | Phase 1|Phase 2 |
NCT02632045 | Melissa K Accordino|Novartis Pharmaceuticals|Columbia University | Metastatic Breast Cancer|Breast Carcinoma | March 2016 | Phase 2 |
NCT02159066 | Pfizer | Melanoma | July 23, 2014 | Phase 2 |
NCT03462251 | iOMEDICO AG|Novartis Pharmaceuticals | Breast Cancer|Hormone Receptor Positive Tumor|HER 2 Negative Breast Cancer | May 24, 2018 | Phase 3 |
NCT03285412 | Massachusetts General Hospital|Novartis | Breast Cancer | December 12, 2017 | Phase 2 |
NCT02657343 | Dana-Farber Cancer Institute|Novartis | Breast Cancer | March 9, 2016 | Phase 1|Phase 2 |
NCT02780128 | Yael P Mosse|Novartis Pharmaceuticals|Foundation Medicine|Children´s Hospital of Philadelphia | Neuroblastoma|Cancer | July 2016 | Phase 1 |